A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Breast Cancer (TNBC)
Phase of Trial: Phase II
Latest Information Update: 02 Feb 2017
At a glance
- Drugs Carboplatin (Primary) ; Doxorubicin liposomal (Primary) ; Paclitaxel (Primary) ; Epirubicin
- Indications Breast cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 19 Jan 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Jul 2018.
- 11 Jun 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.